Enoxaparin: Difference between revisions

(Text replacement - "Cr " to "creatinine ")
No edit summary
Line 1: Line 1:
==General==
==General==
*Type: [[Low molecular weight heparin]]
*Type: [[Low molecular weight heparin]]
*Dosage Forms:
*Dosage Forms: subcutaneous
*Common Trade Names: Lovenox
*Common Trade Names: Lovenox


==Adult Dosing==
==Adult Dosing==
*[[DVT]] ''prophylaxis'': 40mg SC daily
*Therapeutic anticoagulation (e.g. treating DVT/PE, unstable angina): 1mg/kg SC q12h


==Pediatric Dosing==
==Pediatric Dosing==
''Off-label''
*DVT prophylaxis:
**<2 months: 0.75 mg/kg SC q12hr 
**≥2 months: 0.5 mg/kg SC q12h
*Therapeutic anticoagulation:
**<2 months: 1.5 mg/kg SC q12hr
**≥2 months: 1 mg/kg SC q12hr


==Special Populations==
==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]:
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B
*Lactation:
*Lactation: Unknown risk
*Renal Dosing
*Renal Dosing
**Renal impairment (creatinine clearance <30)
**Renal impairment (creatinine clearance <30)
***Use 50% of usual dose or use UFH instead
***Use 50% of usual dose or use UFH instead
**Adult
*Hepatic Dosing: not established
**Pediatric
*Hepatic Dosing
**Adult
**Pediatric
*Obesity
*Obesity
**Weight-based dosing safe up to 190kg (no data available thereafter)
**Weight-based dosing safe up to 190kg (no data available thereafter)
Line 37: Line 42:


==Pharmacology==
==Pharmacology==
*Half-life:  
*Half-life: 4.5h
*Metabolism:  
*Metabolism: hepatic
*Excretion:  
*Excretion: urine
*Mechanism of Action:
*Mechanism of Action: inhibits factor Xa by increasing inhibition rate of clotting proteases that are activated by antithrombin III


==See Also==
==See Also==

Revision as of 19:19, 22 September 2019

General

Adult Dosing

  • DVT prophylaxis: 40mg SC daily
  • Therapeutic anticoagulation (e.g. treating DVT/PE, unstable angina): 1mg/kg SC q12h

Pediatric Dosing

Off-label

  • DVT prophylaxis:
    • <2 months: 0.75 mg/kg SC q12hr
    • ≥2 months: 0.5 mg/kg SC q12h
  • Therapeutic anticoagulation:
    • <2 months: 1.5 mg/kg SC q12hr
    • ≥2 months: 1 mg/kg SC q12hr

Special Populations

  • Pregnancy Rating: B
  • Lactation: Unknown risk
  • Renal Dosing
    • Renal impairment (creatinine clearance <30)
      • Use 50% of usual dose or use UFH instead
  • Hepatic Dosing: not established
  • Obesity
    • Weight-based dosing safe up to 190kg (no data available thereafter)

Indications

Contraindications

  • Allergy to class/drug

Adverse Reactions

  • Bleeding
  • Pruritus
  • Local skin reaction

Pharmacology

  • Half-life: 4.5h
  • Metabolism: hepatic
  • Excretion: urine
  • Mechanism of Action: inhibits factor Xa by increasing inhibition rate of clotting proteases that are activated by antithrombin III

See Also

References